CD274 and cancer: ICIs, such as durvalumab and atezolizumab, targeting programmed cell death ligand-1 (PD-L1), and nivolumab and pembrolizumab, targeting programmed cell death protein-1 (PD-1), are revolutionising the management of common cancers, including lung carcinomas2–4, head and neck5 and skin cancers6.